Historical record - last NADAC effective date: 1/1/2024
Product Information
SUTENT 25 MG CAPSULE is a brand product labeled by Pfizer Inc., priced at $449.0639 per EA under NDC 00069077038. Its NADAC has been published 582 times since Nov 28, 2013.
FDA first approved this application on Jan 26, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/1
Manufacturer
Pfizer Inc.NDC
00069077038
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
1/1/2024
Active Ingredients
SUNITINIB MALATEApproval Type
New Drug (NDA)
FDA Application
NDA021938FDA Approved
1/26/2006
TE Code
AB
On Market Since
1/26/2006
Pharmacological Classes
Price Statistics
The NADAC for SUTENT 25 MG CAPSULE has been published 582 times since Nov 28, 2013, and over the history we have for it it has risen 110.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $449.0639 per EA |
|---|---|
| All-time high | $449.0639 (Jan 15, 2025) |
| All-time low | $213.0708 (Nov 28, 2013) |
| Median price | $356.9855 |
| Average price | $350.8876 |
| Largest weekly change | +7.0% (Jun 11, 2014) |
| Weeks tracked | 582 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+3.0%
5Y
+14.1%
All
+110.8%
Last surveyed Jan 15, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Sunitinib malate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sunitinib malate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUTENT 25 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for SUTENT 25 MG CAPSULE, manufactured by Pfizer Inc., is $449.0639 per EA (NDC 00069077038), effective Jan 15, 2025.
How has the price of SUTENT 25 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for SUTENT 25 MG CAPSULE has risen 110.8%. It has been tracked across 582 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for SUTENT 25 MG CAPSULE?
Since Nov 28, 2013, the NADAC for SUTENT 25 MG CAPSULE has ranged from a low of $213.0708 (Nov 28, 2013) to a high of $449.0639 (Jan 15, 2025), with a median of $356.9855 per EA.
Are there cheaper alternatives to SUTENT 25 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of SUTENT 25 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SUTENT 25 MG CAPSULE?
SUTENT 25 MG CAPSULE (NDC 00069077038) is labeled by Pfizer Inc., and CMS classifies it as a brand product.